This article previews the full ExpertREACT analysis published April 2025. For the complete article with revenue modelling and product-level forecasts, see Can RSV Relieve the Vaccine Industry's Long-Suffering COVID Problem? Current RSV intelligence is in VAMV088 - RSV Adult COMBO Vaccines Forecast.
The COVID Revenue Hangover
The four major vaccine manufacturers experienced an unprecedented revenue surge from COVID-19 vaccines between 2021 and 2022. Pfizer alone reported over $37 billion in Comirnaty revenues in 2022. The hangover that followed has been equally pronounced: by 2024, annual COVID-19 vaccine revenues had declined to a fraction of peak levels, and the trajectory continues downward as booster uptake stabilises at lower-than-anticipated rates in most markets.
Routine vaccination programmes, disrupted during the pandemic, have largely recovered - but not uniformly. Some market categories remain below their pre-pandemic growth trajectories, creating a structural gap in portfolio performance that cannot be filled by legacy products alone.
RSV as the Next Growth Driver
Respiratory syncytial virus vaccines entered commercial reality in 2023 with approvals for Pfizer's Abrysvo and GSK's Arexvy in older adults, followed by maternal indications. Launch data have exceeded expectations in some markets and fallen short in others, but the directional story is clear: RSV vaccination is transitioning from pipeline aspiration to routine practice.
Pfizer's peak annual COVID-19 (Comirnaty) revenues - a level the market does not expect to see again. RSV and combination products are the strategic response.
The Combination Vaccine Opportunity
The most strategically significant development is not RSV vaccines in isolation but the potential for combination respiratory products - RSV/COVID, RSV/influenza, and ultimately tri-valent combinations - to simplify vaccination schedules and improve uptake in older adults. Pfizer's combination RSV/COVID programme and Moderna's mRNA-1230 represent early steps in what could become the dominant adult respiratory vaccine format of the late 2020s.
VacZine Analytics models combination vaccine penetration scenarios in our current RSV Adult COMBO Vaccines Forecast (VAMV088), including payer willingness-to-pay thresholds and co-administration convenience effects on uptake across 14 major markets.
"The question is not whether combination respiratory vaccines will dominate adult immunisation - but which company will lock in formulary position first."
Conclusions
RSV combination vaccines represent the clearest structural growth opportunity in the near-term adult vaccine market. Companies best positioned are those that can demonstrate both clinical differentiation and healthcare system value in a cost-constrained payer environment.